Glomerulonephritis  >>  OPL-CCL2-LPM  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
OPL-CCL2-LPM / CoMentis
NCT00856674: Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy

Terminated
1
30
Canada
OPL-CCL2-LPM, CCL2-LPM, CCL2-SA1 fusion protein
Osprey Pharmaceuticals USA, Inc.
IGA Nephropathy, Proteinuria
06/10
06/10

Download Options